Today: 14 June 2026
Browse Category

NASDAQ:IETC 18 November 2025

Trump’s Tariff Tsunami: 100% Drug Tax and New Import Levies Rock Global Trade

Why iShares U.S. Tech Independence Focused ETF (IETC) Is in the Spotlight as a “Tariff‑Resistant” Play in the Trump Economy – November 18, 2025

U.S. stocks fell for a fourth day November 18 as Trump’s expanded tariffs drove up import costs and rattled markets. The iShares U.S. Tech Independence Focused ETF (IETC) drew investor attention as a possible hedge, focusing on tech firms with domestic operations. Manufacturing has contracted for eight straight months, with most tariff costs falling on U.S. companies and consumers, according to Goldman Sachs.
18 November 2025
··

Stock Market Today

  • Indivior's Chief Scientific Officer Sells Shares Amid Stock Rally: Investor Implications
    June 14, 2026, 12:02 AM EDT. Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals, sold 18,586 shares valued at $707,383 on June 11, 2026, representing 7.54% of his holdings. Post-sale, he retains 227,923 shares worth about $8.69 million, maintaining a 0.18% stake. The sale occurred during a significant stock price surge, with Indivior shares rising 177% over the past year, reflecting strong market performance amid growth in opioid dependence therapies. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, not signaling insider concerns. Indivior's strategy focuses on buprenorphine-based addiction treatments, with $1.29 billion in trailing twelve-month revenue and $252 million net income, underscoring its established market position and ongoing research-led expansion.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop